The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8

More documents

Recommendations

Info

MHV CT liver 2 nd July 09 CT abd Oct 2009 CT abd Jan 2010 CT abd April 2010 SGH – Surgery 38
Pierce Chow FRCSE PhD Can Neoadjuvant therapy with Y90 improve survival after resection ? Histology: Residual hepatocellular carcinoma, Grade 2/4. - 7 cm diameter (from 13 cm) -approximately pp y 50% of tumor show necrosis ppost treatment SGH – Surgery 39
Page 1 and 2: The SIRSA, SIRveNIB, SARAH and SORA
Page 3 and 4: What is the Role of Selective Inter
Page 5 and 6: Outcomes: Survival by yBCLC Stage g
Page 7 and 8: Is there a role for Y90 to be combi
Page 9 and 10: E L I G I B L E P A T I E N T S AHC
Page 11 and 12: Tumour Response Pierce Chow FRCSE P
Page 13 and 14: Comparative Median Survival Asian P
Page 15 and 16: Optimal management of HCC not amend
Page 17 and 18: Asia‐Pacific Sorafenib Trial Over
Page 19 and 20: Asia-Pacific Asia Pacific Hepatocel
Page 21 and 22: Rational i for f comparing i SSIRT
Page 23 and 24: Multi-center Clinical Trials of the
Page 25 and 26: SIRveNIB RCT Milan Pierce Chow FRCS
Page 27 and 28: Pierce Chow FRCSE PhD SIRT yttrium-
Page 29 and 30: SIRveNIB SARAH • N = 360 (1:1) (S
Page 31 and 32: SIRveNIB SARAH • Study schedule:
Page 33 and 34: Pierce Chow FRCSE PhD Hepatocellula
Page 35 and 36: 1⁰ endpoint SORAMIC Trial: Schema
Page 37: Outcomes of Resection for Marginal
Page 41: Thank You! Pierce Chow FRCSE PhD SG

The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?